1
|
Alvarez RH, Koenig KB, Ensor JE, Ibrahim NK, Chavez-MacGregor M, Litton JK, Schwartz Gomez JK, Cyriac A, Krishnamurty S, Caudle AS, Shaitelman SF, Whitman GJ, Booser DJ, Reuben JM, Valero V. Abstract P1-14-04: A randomized phase II neoadjuvant (NACT) study of sequential eribulin followed by FAC/FEC-regimen compared to sequential paclitaxel followed by FAC/FEC-regimen in patients (pts) with operable breast cancer not overexpressing HER-2. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-14-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Neoadjuvant chemotherapy (NACT) is an integral component for locally advanced and large operable breast cancer. The sequence of taxanes followed by anthracyclines has been the standard of care for almost 20 years. Eribulin (E) is a synthetic analogue of halichondrin B with distinct mechanism of action as microtubule dynamics inhibitor. The FDA approved E in 11/2010 for the treatment of patients (pts) with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Research Hypothesis: Sequential administration of eribulin followed by FAC/FEC-regimen, would have greater pathologic complete response (pCR) rate than sequential administration of paclitaxel followed by FAC/FEC-regimen as primary systemic therapy for woman with operable breast cancer.
Methods: This is a phase II, randomized, single institution, open label study. Pts were randomized 1:1 to receive E (1.4 mg/m2 d1 and d8 q 21 days x 4) or paclitaxel (P) (80 mg/m2 weekly x12). Both arms received FAC/FEC regimen x 4 doses followed by surgery. Eligible pts were women age 18 or older, Karnosfky PS 80 – 100, histologically confirmed invasive breast cancer, clinical T2-T3, N0-3, M0, HER2-negative. Baseline LVEF of > 50% and normal hematology, liver and kidney laboratory function tests. Primary endpoint was pathologic complete response (pCR/RCB-0) assessed by residual cancer burden (RCB). [Symmans F, 2007]. This protocol (2012-0167) IRB of The University of Texas, MD Anderson Cancer Center.
Results: A preplanned interim analysis aimed to validate trial assumption was conducted after treatment of 54 randomized pts. Between 8/2012 to 7/2014, 54 pts were randomized and 49 were evaluable for pCR(27 P arm and 22 E arm). Tumor response by RCB is shown in the table. pCR rates were 30% and 4.5% in the P and E arm, respectively.
Table 1.ResponsePaclitaxel - FAC/FEC Arm (N=27)Eribulin - FAC/FEC Arm (N=22)RCB 0 (pCR)8 (30%)1 (4.5%)RCB I6 (22.2%)1 (4.5%)RCB II9 (33%)10 (45%)RCB III4 (14.8%)10 (45%)
53 pts were evaluable for toxicity. The combination was safe with mostly grade 1 and 2 toxicities in both arms. In the P arm grade 3 peripheral neuropathy and neutropenia was seen in 3% and 7%, respectively. In the E arm one patient died due to multiorgan failure during cycle 1. There was no other grade 3-5 toxicity. Biomarker analysis using CTCs by AdnaTest Breast were evaluated in 39 pts at baseline. 5/39 pts were positive for CTCs. 3 pts had transcripts for EpCAM, 1 for Muc-1 and another had both. 30 pts had an additional sample post therapy. 2 pts were positive for CTC at baseline as well as at follow up (FU) visit at 180 days. None of the samples showed CTC-EMT at baseline or at FU visits.
Conclusions: The interim analysis demonstrated that E arm lead to significantly lower pCR/RCB1 rate compared to P arm. Ongoing biomarker analyses include TIL, hot spot mutation analysis (HSMA) and molecular inversion probes (MIP) will be presented at the time of the meeting. Clinical trial information: NCT01593020.
Citation Format: Alvarez RH, Koenig KB, Ensor JE, Ibrahim NK, Chavez-MacGregor M, Litton JK, Schwartz Gomez JK, Cyriac A, Krishnamurty S, Caudle AS, Shaitelman SF, Whitman GJ, Booser DJ, Reuben JM, Valero V. A randomized phase II neoadjuvant (NACT) study of sequential eribulin followed by FAC/FEC-regimen compared to sequential paclitaxel followed by FAC/FEC-regimen in patients (pts) with operable breast cancer not overexpressing HER-2. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-14-04.
Collapse
Affiliation(s)
| | - KB Koenig
- MD Anderson Cancer Center, Houston, TX
| | - JE Ensor
- MD Anderson Cancer Center, Houston, TX
| | | | | | - JK Litton
- MD Anderson Cancer Center, Houston, TX
| | | | - A Cyriac
- MD Anderson Cancer Center, Houston, TX
| | | | - AS Caudle
- MD Anderson Cancer Center, Houston, TX
| | | | | | - DJ Booser
- MD Anderson Cancer Center, Houston, TX
| | - JM Reuben
- MD Anderson Cancer Center, Houston, TX
| | - V Valero
- MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
2
|
Basho RK, Gilcrease M, Murthy RK, Helgason T, Booser DJ, Karp DD, Meric-Bernstam F, Wheler JJ, Valero V, Albarracin C, Litton J, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder S. Abstract P3-14-02: Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer (TNBC): Evidence of efficacy and proof of concept from a phase I trial with dose expansion of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-14-02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Approximately 30% of TNBCs are characterized by microarray as claudin-low, mesenchymal or mesenchymal stem cell-like and, unlike basal TNBCs, these tumors frequently harbor aberrations in the PI3K/AKT/mTOR axis, raising the possibility of targeting this axis to enhance chemotherapy response. Assays to clinically identify mesenchymal TNBCs are under development, but published results confirm that up to 30% are metaplastic breast cancers (MpBCs), a chemo-refractory group of tumors that contain a mixture of epithelial and mesenchymal components, making them identifiable by microscopy. As such, MpBCs serve as surrogates of response for potential regimens to treat mesenchymal TNBC.
Methods: Patients (pts) with advanced TNBC (N=64) were treated with liposomal doxorubicin (D), bevacizumab (A) and the mTOR inhibitors temsirolimus (T) or everolimus (E). D and A were administered IV on day 1 with T (IV on days 1, 8 and 15) or E (continuous daily oral administration) using 21 day cycles. Response was assessed every 6 weeks using RECIST. When available, archived tissue was evaluated for aberrations in the PI3K pathway using standard assays.
Results: Fifty-two MpBC pts were treated with DAT (N=39) or DAE (N=13). Median age was 58 (range 37-79); median # of prior regimens for metastatic disease was 1 (range 0-5). The objective response rate (ORR) was 21% [complete response (CR)=4 (8%); partial response (PR)=7 (13%)] and 10 (19%) pts had stable disease (SD)≥6 months for a clinical benefit rate (CBR) of 40%. Tissue was available for testing in 43 pts and 32 (74%) had a PI3K pathway activating aberration (Table 1).
Response According to PI3K Pathway AberrationPI3K Pathway AberrationN (%)CRPRSD≥6monthsCBRORRAny PI3K Pathway Aberration*32 (74)46444%31%PIK3CA Mutation19 (59)23447%26%p.H1047R12 (38)21350%25%p.E545K6 (19)02150%33%p.G1007R1 (3)010100%100%p.E545A1 (3)0000%0%p.H1047Y1 (3)0000%0%p.K111E1 (3)0000%0%p.E542K1 (3)0000%0%PIK3CA Amplification1 (3)010100%100%PTEN Mutation5 (16)0000%0%PTEN Loss5 (16)02040%40%AKT1 p.E17K Mutation2 (6)0000%0%AKT2 Amplification1 (3)100100%100%PIK3R1 Mutation2 (6)01050%50%NF2 Mutation1 (3)100100%100%No PI3K Pathway Aberration11 (26)00545%0%*Some tumors had >1 aberration detected
PI3K pathway activation was associated with a significant improvement in ORR (31 vs 0%; P=0.043) but not CBR (44 vs 45%; P=1.000) or progression-free survival (median 5.1 vs 2.9 months; P=0.352). A pt with 5 year+ durable CR (on maintenance everolimus) had a mutation in NF2. To emphasize the importance of pt selection, it is notable that 12 pts with non-metaplastic TNBC were also treated with DAT, and only 1 pt had a response (CR/PR=1; SD≥6 months=0), for a CBR that was significantly worse than pts with MpBC (8 vs 40%; P=0.045).
Conclusions: Using MpBC as a surrogate of response, DAT/DAE has significantly better activity in mesenchymal compared to non-selected TNBC. Response is enhanced in pts with PI3K pathway activation. DAT/DAE should be tested in non-metaplastic, mesenchymal TNBC once a diagnostic assay is available.
Citation Format: Basho RK, Gilcrease M, Murthy RK, Helgason T, Booser DJ, Karp DD, Meric-Bernstam F, Wheler JJ, Valero V, Albarracin C, Litton J, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder S. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer (TNBC): Evidence of efficacy and proof of concept from a phase I trial with dose expansion of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-14-02.
Collapse
Affiliation(s)
- RK Basho
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - M Gilcrease
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - RK Murthy
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - T Helgason
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - DJ Booser
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - DD Karp
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - F Meric-Bernstam
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - JJ Wheler
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - V Valero
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - C Albarracin
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - J Litton
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - M Chavez-MacGregor
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - NK Ibrahim
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - JL Murray
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - KB Koenig
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - D Hong
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - V Subbiah
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - R Kurzrock
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - F Janku
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| | - S Moulder
- The University of Texas MD Anderson Cancer Center, Houston, TX; UC San Diego Moores Cancer Center, La Jolla, CA
| |
Collapse
|
3
|
Lim B, Jackson S, Alvarez RH, Ibrahim NK, Willey JS, Murthy RK, Booser DJ, Giordano SH, Barcenas CH, Brewster A, Walters RS, Brown PH, Tripathy D, Valero V, Ueno NT. Abstract P4-14-22: A single-center, open-label phase 1b study of entinostat, and lapatinib alone, and in combination with and trastuzumab in patients with HER2+ metastatic breast cancer after progression on trastuzumab. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-14-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Our in vitro and in vivo preclinical data showed that entinostat enhances the efficacy of lapatinib in HER2 positive (HER2+) breast cancer cells via FOXO3-mediated Bim1 expression, which resulted in enhanced apoptosis in HER2 targeted therapy (lapatinib and trastuzumab)-resistant breast cancer (IBC and non-IBC) cells [Lee et al.]. Based on these findings, we conducted a phase 1b trial of entinostat to determine the maximal tolerated dose (MTD) in combination with lapatinib alone and in combination with lapatinib and trastuzumab for metastatic HER2+ breast cancer patients (pts), who progressed on trastuzumab.
Method: This was a single-center, open-label phase 1b study to evaluate the dose limiting toxicity (DLT) and determine MTD. 3+3 dose escalation schedule was used for Cohorts 1 and 2. Pts received lapatinib and entinostat (Cohort 1) or entinostat, lapatinib, and trastuzumab (Cohort 2). Initial dose of lapatinib 1250mg in Cohort 1 and 1000mg for Cohort 2 to match standard dose in combination with trastuzumab dose. In Cohort 1, entinostat was given PO on day 1 and 15 every 28 days cycle at dose levels 10 mg (level 0), 12 mg (level 1), or 15 mg (level 2). The dose levels for Cohort 2 were 12 mg (co-level 0) or 15 mg (co-level 1) on day 1 and 15 every 28 days cycle. While lapatinib and entinostat were given 28 days cycle due to entinostat dosing, the dosing of trastuzumab followed approved schedule every 21 days starting at 8mg/kg loading followed by 6mg/kg q 3 wks in Cohort 2 and 3. After the MTD of entinostat in cohort 2 was determined at 12mg, an expansion cohort of 10 pts (cohort 3) was conducted.
Results: Median age was 52 (26-69 yrs). Median number of prior trastuzumab-based regimens was 2 (1-6), 8 pts had lapatinib containing treatment prior to the trial, including 5 pts who had clinical benefit. 16 had ER+ and 13 ER negative, and 9 had IBC. Clinical efficacy and toxicity of treatment is summarized in table 1. Out of 14 pts who had clinical benefit (CR, PR, SD), 6 had IBC. Three pts are still on therapy (1CR, 1PR, 1SD).
Table 1. Clinical Efficacy, Toxicity of combination Receptor StatusResponseGrade 3 toxicityGrade 4 toxicityCohort 1HER2+/ER- (N=8) HER2+/ER+ (N=7)CR (N=1; 8M), SD (N=4;1,2,4M)Lapatinib dose reduction: 3 pts Rash (2) Abdominal pain + dyspnea (1)Entinostat dose reduction: 2pts Neutropenia (1 at 12mg, 1 at 15mg)Cohort 2/3HER2+/ER- (N=8) HER2+/ER+ (N=6)CR (N=2; 3,6M), PR (N=2;4,5M) SD (N=5;1,2,4,6M)Lapatinib dose reduction: 2 pts Diarrhea (N=1 at 12mg N=1 at 10mg) Entinostat dose reduction: 5 pts Neutropenia (N=2 at 12 mg) Leukopenia (N=1 at 12mg) Anemia (N=1 at 12mg)Entinostat dose reduction: 2pts Hypokalemia (N=1 at 12mg) Thrombocytopenia (N=1 at 15mg)CR: complete response, PR: partial response, SD: stable disease, N=number of pts, M=months
Conclusion: MTD was reached at 12mg q 2wkly entinostat, lapatinib 1000 mg daily and trastuzumab 8 mg/kg followed by 6mg/kg q 3 wks. This combination was safe and had promising clinical efficacy in patients with trastuzumab-resistant metastatic HER2+ breast cancer including IBC, warranting further study.
Citation Format: Lim B, Jackson S, Alvarez RH, Ibrahim NK, Willey JS, Murthy RK, Booser DJ, Giordano SH, Barcenas CH, Brewster A, Walters RS, Brown PH, Tripathy D, Valero V, Ueno NT. A single-center, open-label phase 1b study of entinostat, and lapatinib alone, and in combination with and trastuzumab in patients with HER2+ metastatic breast cancer after progression on trastuzumab. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-14-22.
Collapse
Affiliation(s)
- B Lim
- The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX
| | - S Jackson
- The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX
| | - RH Alvarez
- The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX
| | - NK Ibrahim
- The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX
| | - JS Willey
- The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX
| | - RK Murthy
- The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX
| | - DJ Booser
- The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX
| | - SH Giordano
- The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX
| | - CH Barcenas
- The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX
| | - A Brewster
- The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX
| | - RS Walters
- The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX
| | - PH Brown
- The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX
| | - D Tripathy
- The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX
| | - V Valero
- The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX
| | - NT Ueno
- The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX
| |
Collapse
|
4
|
Ueno NT, Jackson SA, Alvarez RH, Willey JS, Hortobagyi GN, Angulo-Gonzalez AM, Giordano SH, Booser DJ, Valero V. Abstract P5-20-13: Preliminary report of a phase I/II study of entinostat (IND#NSC 706995, /M275) and lapatinib (IND#NSC 727989) in patients with HER2-positive metastatic breast cancer in whom trastuzumab has failed. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-20-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Entinostat is a novel, potent, orally bioavailable, class I selective histone deacetylase inhibitor. Pre-clinical data has shown that Entinostat can enhance the activity of Lapatinib in HER2+ metastatic inflammatory and non-inflammatory breast cancer. The primary objective of the phase I portion of this study is to determine the recommended phase II dose for Entinostat in combination with Lapatinib in patients who have received Trastuzumab for HER2+ metastatic breast cancer.
Methods: This is a single center, open-label study to evaluate the safety and tolerability of every other week entinostat in combination with a 28-day cycle of Lapatinib. Patients with metastatic breast cancer in whom trastuzumab has failed were included. The phase I portion of the study is a conventional 3+3 dose-escalation design. Dose levels include 0 (starting dose) Entinostat 10 mg orally every other week, I Entinostat 12 mg, and II Entinostat 15 mg. Lapatinib 1,250 mg orally is given every day without dose escalation. Toxicities are evaluated at the end of each cycle.
Results: Here we report the phase I portion of the study. To date, 9 patients were enrolled, 3 were in level 0, and 6 were in level I. In Level 0, 2 patients were taken off study due to disease progression (PD) at the end of cycle one and 1 patient was taken off study due to PD at the end of cycle two. In Level I, 1 patient was taken off study due to PD at the end of cycle one and 2 patients were taken off study due to PD at the end of cycle 2. 1 patient had stable disease. The median age is 41 (range, 26–69). Seven of the nine patients are evaluable for toxicity. Most common toxicities reported by the patients are nausea grade 3 (1), fatigue grade 3 (1), muscle aches/pain grade 2 (3), skin rash grade 3 (1), paresthesias grade 2 (2), heartburn grade 1 (4), and diarrhea Grade 2 (1). Lapatinib dose was reduced in 2 patients. The most common hematological toxicities were neutropenia grade 1 (3), anemia grade 2 (1), and thrombocytopenia grade 4 (1).
Conclusions: Overall, patients have tolerated the combination regimen relatively well. We have not reached the maximum tolerated dose, so patient enrollment will continue until the phase I portion of the study is complete, most likely in July 2012. We plan to proceed with phase II portion in two parallel cohorts (HER2+ inflammatory and non-inflammatory metastatic breast cancer).
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-20-13.
Collapse
Affiliation(s)
- NT Ueno
- Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas, MD Anderson Cancer Center, Houston, TX
| | - SA Jackson
- Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas, MD Anderson Cancer Center, Houston, TX
| | - RH Alvarez
- Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas, MD Anderson Cancer Center, Houston, TX
| | - JS Willey
- Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas, MD Anderson Cancer Center, Houston, TX
| | - GN Hortobagyi
- Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas, MD Anderson Cancer Center, Houston, TX
| | - AM Angulo-Gonzalez
- Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas, MD Anderson Cancer Center, Houston, TX
| | - SH Giordano
- Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas, MD Anderson Cancer Center, Houston, TX
| | - DJ Booser
- Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas, MD Anderson Cancer Center, Houston, TX
| | - V Valero
- Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas, MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
5
|
Kelly CM, Green MC, Broglio K, Pusztai L, Thomas E, Brewster A, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Hunt K, Hortobagyi GN, Buzdar A. Capecitabine in operable triple receptor–negative breast cancer: A subgroup analysis of a randomized phase III trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.292] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
292 Background: Recent data suggest that patients with operable triple negative breast cancer (TNBC) may derive greater benefit from the addition of capecitabine to anthracycline-taxane regimens. Methods: We examined pathological complete response (pCR), relapse-free survival (RFS) and overall survival (OS) in patients with TNBC randomized to paclitaxel 80mg/m2 weekly (WP) x 12 followed by fluorouracil (500mg/m2), epirubicin (100mg/m2), cyclophosphamide (500mg/m2) every 3 weeks x 4 cycles (FEC) vs. docetaxel (75mg/m2) 3 weekly and capecitabine D1-14 (1500mg/m2 daily; DX) followed by FEC. Patients were stratified by timing of chemotherapy (preoperative vs. adjuvant). Results: 149 patients with TNBC comprising 25% of all patients randomized (N=601). Median age; 49 years (IQR; 41 to 55). The number and proportion of patients by stage were; I (n=32: 21.5%), IIA (n=72: 48.3%), IIB (n=34: 22.8%), IIIA (n=9: 6.0%) and IIIC (n=2; 1.3%). Preoperative therapy was administered to 58 patients (39%) and adjuvant to 91 (61%). There were 17 events (21%) in the DX arm and 10 events (15%) in the WP arm (P=0.36) including 11 distant recurrences in the DX arm and 9 in the WP arm (P=0.99). We observed a pCR in 11 patients (37%) and 10 (36%) in the DX and WP arms respectively (P=0.94). The odds ratio for pCR for patients with TNBC given DX vs. WP was 0.98 (95% CI; 0.33 to 2.80: P=0.94). At 50-months median follow-up the RFS and OS in patients with TNBC randomized to DX or WP was 77% (66 to 86%) and 83% (73 to 92%) (P=0.41) and 78% (67 to 87%) and 87% (77 to 95%) (P=0.16) respectively. RFS and OS for WP vs. DX for non-TNBC was 93% (87 to 95%) and 92% (88 to 96%) (p=0.91) and 96% (92 to 98%) and 97% (94 to 99%) for WP and DX respectively (P=0.39). Conclusions: In this unplanned subgroup analysis there was no difference in pCR, RFS or OS in patients with operable TNBC randomized to WP or DX however, power is limited and should be considered when interpreting these data.
Collapse
Affiliation(s)
- C. M. Kelly
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - M. C. Green
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - K. Broglio
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - L. Pusztai
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - E. Thomas
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - A. Brewster
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - V. Valero
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - N. K. Ibrahim
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | | - D. J. Booser
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - K. Hunt
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | | - A. Buzdar
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
6
|
Symmans WF, Hatzis C, Valero V, Booser DJ, Esserman L, Martin M, Vidaurre T, Holmes F, Souchon EA, Lluch A, Cotrina J, Gomez H, Hubbard R, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Pusztai L. M. Abstract PD07-03: A Genomic Predictor of Survival Following Taxane-Anthracycline Chemotherapy for Breast Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-pd07-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: There is currently no predictive assay for patients with clinical Stage II-III breast cancer from which predicted sensitivity to treatment is associated with high probability of survival following chemotherapy.
Patients & Methods: We performed Affymetrix gene expression microarrays of prospectively collected tumor biopsies from 508 patients with newly diagnosed HER2-normal invasive breast cancer prior to neoadjuvant taxane-anthracycline chemotherapy followed by adjuvant endocrine therapy (if hormone receptor-positive). The predictor was developed from 310 samples (from MDACC & I-SPY) by combining: 1) a signature to predict sensitivity to endocrine therapy (SET); 2) estrogen receptor (ER)-stratified predictive signatures of resistance to chemotherapy, defined as extensive residual cancer burden (RCB-III) or relapse within 3 years; and 3) ER-stratified predictive signatures of response to chemotherapy, defined as pathologic complete response (pCR) or minimal RCB (RCB-I). The predictor classified tumors as treatment sensitive if high or intermediate SET, or if predicted to be responsive (and not resistant) to chemotherapy. Otherwise, tumors were classified as treatment insensitive. The predictor was then tested on an independent cohort (N= 198, 98% with clinical Stage II-III) who received neoadjuvant (N= 180) or adjuvant (N= 18) taxane-anthracycline chemotherapy (from MDACC, USO, GEICAM, Peru, LBJ). Distant relapse-free survival (DRFS) was evaluated at a 3-year median follow up using negative predictive value (NPV, absence of event if predicted to be sensitive), and absolute risk reduction (ARR) for those predicted to be sensitive (versus insensitive), with 95% confidence interval (CI). The independent predictive value was assessed in multivariate Cox regression analysis based on the likelihood ratio test (P≥0.05). Results: Patients in the independent validation cohort who were predicted to be treatment sensitive (28%) had excellent DRFS, with NPV 92% (CI 85-100) and significant absolute risk reduction (ARR 18%, CI 6-28) at 3 years, compared to those predicted to be insensitive. This was similar to the DRFS observed in patients who achieved pCR after they completed neoadjuvant chemotherapy (NPV 93%, CI 85-100). Predictions were accurate in each phenotypic subset: ER+/HER2- (30% predicted sensitive, NPV 97%, CI 91-100; ARR 11%, CI 0.1-21) and ER-/HER2- (26% predicted sensitive, NPV 83%, CI 68-100; ARR 26%, CI 4-28). Predicted treatment sensitivity (HR 0.20, CI 0.07-0.57), ER+ status (HR 0.32, CI 0.17-0.63), clinical tumor stage T3-4 (HR 2.04, CI 1.07-3.88) and age >50 (HR 0.50, CI 0.25-0.98) were significant in a multivariate model that also included clinical nodal status, grade, and type of taxane used.
Conclusion: We report validation results for the first molecular predictor of sensitivity to neoadjuvant/adjuvant systemic therapy for clinical Stage II-III breast cancer that is independently associated with excellent DRFS in those predicted to be sensitive. Predictions were accurate for both ER+/HER2- and ER-/HER2- invasive breast cancer.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD07-03.
Collapse
Affiliation(s)
- WF Symmans
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - C Hatzis
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - V Valero
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - DJ Booser
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - L Esserman
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - M Martin
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - T Vidaurre
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - F Holmes
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - EA Souchon
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - A Lluch
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - J Cotrina
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - H Gomez
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - R Hubbard
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - J Ferrer-Lozano
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - R Dyer
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - M Buxton
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - Y Gong
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - Y Wu
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - N Ibrahim
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - E Andreopoulou
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - NT Ueno
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - K Hunt
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - W Yang
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - A Nazario
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - A DeMichele
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - J O'Shaughnessy
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - GN Hortobagyi
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| | - M.D. Pusztai L.
- Anderson Cancer Center; Nuvera Biosciences, Inc.; I-SPY Clinical Trial Investigators; GEICAM Investigators, Spain; Instituto Nacional de Enfermedades Neoplacicas, Lima, Peru; US Oncology; Lyndon B. Johnson Hospital, Houston; US Oncology/Baylor Sammmons Cancer Center, Dallas
| |
Collapse
|
7
|
Morrow PH, Wulf GM, Booser DJ, Moore JA, Flores PR, Krop IE, Winer EP, Hortobagyi GN, Yu D, Esteva FJ. Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1014] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Santarpia L, Gonzalez-Angulo AM, Qi Y, Stemke-Hale K, Wang B, Booser DJ, Hortobagyi GN, Symmans WF, Di Leo A, Pusztai L. Use of mutation profiling of breast cancer using sequenom technology to detect distinct mutation patterns in triple-negative compared to receptor-positive cancers. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol 2008; 19:1713-9. [PMID: 18515258 DOI: 10.1093/annonc/mdn352] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Novel molecular therapies for metastatic breast cancer (MBC) are necessary to improve the dismal prognosis of this condition. Imatinib mesylate (Gleevec) inhibits several protein tyrosine kinases, including platelet-derived growth factor receptor (PDGFR) and c-kit, which are preferentially expressed in tumor cells. We tested the activity of imatinib mesylate in MBC with overexpression of PDGFR or c-kit. Additionally, we sought to determine the biological correlates and immunomodulatory effects. PATIENTS AND METHODS Thirteen patients were treated with Imatinib administered orally at 400 mg p.o. b.i.d. (800 mg/day), until disease progression. All patients demonstrated PDGFR-beta overexpression and none showed c-kit expression. RESULTS No objective responses were observed among the 13 patients treated in an intention-to-treat analysis. All patients experienced disease progression, with a median time to progression of 1.2 months. Twelve patients have died, and the median overall survival was 7.7 months. No patient had a serious adverse event. Imatinib therapy had no effect on the plasma levels of the angiogenesis-related cytokines, vascular endothelial growth factor, PDGF, b-fibroblast growth factor, and E-selectin. Immune studies showed imatinib inhibits interferon-gamma production by TCR-activated CD4(+) T cells. CONCLUSION Imatinib as a single agent has no clinical activity in PDGFR-overexpressing MBC and has potential immunosuppressive effects.
Collapse
Affiliation(s)
- M Cristofanilli
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Hatzis C, Symmans WF, Lin F, Zheng B, Yan K, Booser DJ, Gong Y, Valero V, Hortobagyi GN, Pusztai L. Genomic predictors of pathologic response to preoperative chemotherapy for triple-negative and ER-positive/HER2-negative breast cancers. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.571] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Alvarez RH, Kau S, Strom EA, Sahin AA, Singletary SE, Booser DJ, Cristofanilli M, Esteva FJ, Hortobagyi GN, Valero V. Phase II study of primary systemic therapy (PST) with doxorubicin (D) and docetaxel (T), then surgery (S), and radiation (RT), followed by use of non-cross-resistant adjuvant chemotherapy (Adj CT) with CMF based on pathologic response, in patients (pts) with locally advanced breast cancer (LABC): Long-term results from study ID97–099, M. D. Anderson Cancer Center. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.611] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S, Esseltine D, Stec J, Broglio KR, Islam R, Hortobagyi GN, Cristofanilli M. Bortezomib (VELCADE®) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 2006; 17:813-7. [PMID: 16403809 DOI: 10.1093/annonc/mdj131] [Citation(s) in RCA: 99] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Bortezomib (VELCADE) is a potent inhibitor of the 26S proteasome with broad antitumor activity. We performed a phase II study of bortezomib to evaluate its clinical effects in patients with metastatic breast cancer. PATIENTS AND METHODS Twelve patients with metastatic breast cancer were treated with bortezomib (VELCADE) at a dosage of 1.5 mg/m(2) administered biweekly for 2 weeks with 1 week of rest in a 21-day cycle. The primary objective was clinical response rate. Toxicity and pharmacodynamics data were also obtained. RESULTS No objective responses were observed. One patient had stable disease, and 11 others experienced disease progression. The median survival time was 4.3 months (range, 0.9-37 months). The most common grade 3 or 4 toxicities included fatigue (58%; n = 7) and skin rash (33%; n = 4). The mean inhibition of specific chymotryptic activity was 53.1% (+/- 13.33%). A statistically significant reduction in the plasma interleukin-6 level was seen (P = 0.0354). CONCLUSION Bortezomib was well tolerated but showed limited clinical activity against metastatic breast cancer when used as a single agent. The future development of this agent for the treatment of breast cancer should be guided by in vivo models that optimize activity in combination with other antitumor agents.
Collapse
Affiliation(s)
- C H Yang
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Booser DJ, Ueno NT, Rondon G, Williams PA, Wendt R, Hortobagyi GN, Podoloff DA, Champlin RE. Complete response of bone-only metastatic breast cancer to skeletal: Targeted radiotherapy with 166HOLMIUM-DOTMP. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - N. T. Ueno
- UT M. D. Anderson Cancer Ctr, Houston, TX
| | - G. Rondon
- UT M. D. Anderson Cancer Ctr, Houston, TX
| | | | - R. Wendt
- UT M. D. Anderson Cancer Ctr, Houston, TX
| | | | | | | |
Collapse
|
14
|
Michaud LB, Rivera E, Madden T, Esparza-Guerra L, Booser DJ, Green MC, Bradshaw GR, Hortobagyi GN, Valero V. Taxanes in metastatic breast cancer patients with impaired liver function. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.609] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - E. Rivera
- M.D. Anderson Cancer Ctr, Houston, TX
| | - T. Madden
- M.D. Anderson Cancer Ctr, Houston, TX
| | | | | | | | | | | | - V. Valero
- M.D. Anderson Cancer Ctr, Houston, TX
| |
Collapse
|
15
|
Hanrahan EO, Frye D, Buzdar AU, Theriault RL, Booser DJ, Valero V, Singletary SE, Gajewski JL, Champlin RE, Hortobagyi GN. Twelve-year follow-up of a randomized trial of high-dose chemotherapy (HDC) and autologous hematopoietic stem cell support (ASCS) for high-risk primary breast carcinoma. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.663] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - D. Frye
- Univ of Texas M. D. Anderson Cancer Ctr, Houston, TX
| | - A. U. Buzdar
- Univ of Texas M. D. Anderson Cancer Ctr, Houston, TX
| | | | - D. J. Booser
- Univ of Texas M. D. Anderson Cancer Ctr, Houston, TX
| | - V. Valero
- Univ of Texas M. D. Anderson Cancer Ctr, Houston, TX
| | | | | | | | | |
Collapse
|
16
|
Symmans WF, Sotiriou C, Anderson KS, Valero V, Booser DJ, Hess KR, Ross JS, Piccart M, Hortobagyi GN, Pusztai L. Use of DNA microarrays to determine estrogen and HER-2 receptor status in breast cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- W. F. Symmans
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - C. Sotiriou
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - K. S. Anderson
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - V. Valero
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - D. J. Booser
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - K. R. Hess
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - J. S. Ross
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - M. Piccart
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - G. N. Hortobagyi
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| | - L. Pusztai
- UT M. D. Anderson Cancer Ctr, Houston, TX; Inst Jules Bordet, Brussels, Belgium; Millennium Pharmaceuticals, Inc, Cambridge, MA
| |
Collapse
|
17
|
Hortobagyi GN, Kau SW, Buzdar AU, Theriault RL, Booser DJ, Gwyn K, Valero V. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.585] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - S.-W. Kau
- UT M. D. Anderson Cancer Center, Houston, TX
| | | | | | | | - K. Gwyn
- UT M. D. Anderson Cancer Center, Houston, TX
| | - V. Valero
- UT M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
18
|
Esteva FJ, Madden TL, Lammey J, Symmans WF, Booser DJ, Arun B, Rivera E, Brewster AM, Valero V, Hortobagyi GN. Phase I and pharmacokinetic (PK) study of oblimersen, a proapoptotic Bcl-2 targeting oligonucleotide, in combination with doxorubicin and docetaxel in metastatic and locally advanced breast cancer (BC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. J. Esteva
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | - T. L. Madden
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | - J. Lammey
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | | | - D. J. Booser
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | - B. Arun
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | - E. Rivera
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | | | - V. Valero
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
19
|
Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest 2001; 19:459-66. [PMID: 11458813 DOI: 10.1081/cnv-100103844] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Vinorelbine (Navelbine) has significant activity against breast carcinoma and is less neurotoxic than vinblastine. Because vinblastine has improved activity when administered by continuous infusion, we conducted a Phase I-II study to determine the maximum tolerated dose (MTD) of vinorelbine when given by continuous infusion and the response rates to it in heavily pretreated metastatic breast cancer patients. Between April 1994 and August 1997, 87 patients were entered in the study. All were female and had proven metastatic breast cancer. Ninety-five percent of them had received prior doxorubicin treatment, and 74% had received prior paclitaxel treatment. In Phase I of the study, all patients received 8 mg of vinorelbine by intravenous (i.v.) bolus followed by a continuous infusion of vinorelbine over 96 hr. When the MTD was determined, patients were entered in the Phase II arm to assess treatment responses and cumulative toxic reactions. In the Phase I arm (43 patients, 182 cycles), we determined the MTD of vinorelbine to be 8 mg by i.v. bolus followed by a continuous infusion of 11 mg/m2/day over 4 days. The dose-limiting toxic reaction was grade 3-4 granulocytopenia in 35% of the cycles and neutropenic fever in 15% of the cycles. Forty-four patients (193 cycles) were treated at the MTD. Seven (16%) of them had a response (2 complete responses, 5 partial responses). The median durations of response and survival were 4.3 and 8.6 months, respectively. However, cumulative toxic reactions (neutropenic fever and stomatitis) in 22 patients (50%) required dose reductions. A continuous infusion of vinorelbine can be safely administered but with a narrow therapeutic index because of cumulative toxic reactions. We recommend a modified MTD of vinorelbine: 8 mg by i.v. bolus followed by a continuous infusion of 10 mg/m2/day over 4 days. However, this treatment schedule offers no apparent advantage over the commonly used weekly vinorelbine schedule.
Collapse
Affiliation(s)
- N K Ibrahim
- Division of Medicine, Department of Breast Medical Oncology, Box 56, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Booser DJ, Perez-Soler R, Cossum P, Esparza-Guerra L, Wu QP, Zou Y, Priebe W, Hortobagyi GN. Phase I study of liposomal annamycin. Cancer Chemother Pharmacol 2001; 46:427-32. [PMID: 11127949 DOI: 10.1007/s002800000177] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Annamycin is a highly lipophilic anthracycline with the ability to bypass the MDR-1 mechanism of cellular drug resistance. In this phase I study, annamycin entrapped in liposomes was administered by a 1- to 2-h intravenous infusion at 3-week intervals. Thirty-six patients with relapsed solid tumors were treated and 109 courses were administered at doses ranging from 3 to 240 mg/m2. The dose-limiting toxicity was thrombocytopenia. Five patients had a probable allergic reaction, requiring discontinuation of treatment in one. Treatment was well tolerated otherwise. No cardiac toxicity was seen on endomyocardial biopsy of four patients studied. There was limited gastrointestinal toxicity and no alopecia. No objective tumor responses were observed. Pharmacokinetic studies at 24, 120 and 240 mg/m2 showed a biexponential plasma concentration-versus-time profile. There was a linear relationship between the dose and the maximal plasma concentration with relatively constant plasma clearance values. The maximum tolerated dose (MTD) for liposomal annamycin defined in this study is 210 mg/m2. Because of a subsequent change in the formulation of the drug, future studies will use 190 mg/m2 as the MTD.
Collapse
Affiliation(s)
- D J Booser
- Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030-4095, USA
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Brito RA, Valero V, Buzdar AU, Booser DJ, Ames F, Strom E, Ross M, Theriault RL, Frye D, Kau SW, Asmar L, McNeese M, Singletary SE, Hortobagyi GN. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 2001; 19:628-33. [PMID: 11157012 DOI: 10.1200/jco.2001.19.3.628] [Citation(s) in RCA: 141] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
PURPOSE To determine outcomes in local-regional control, disease-free survival, and overall survival in patients with locally advanced breast cancer (LABC) who present with ipsilateral supraclavicular metastases and who are treated with combined-modality therapy. PATIENTS AND METHODS Seventy patients with regional stage IV LABC, which is defined by our institution as LABC with ipsilateral supraclavicular adenopathy without evidence of distant disease, received treatment on three prospective trials of neoadjuvant chemotherapy. All patients received neoadjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil, or cyclophosphamide, doxorubicin, vincristine, and prednisone. Patients then received local therapy that consisted of either total mastectomy and axillary lymph node dissection (ALND) or segmental mastectomy and ALND before or after irradiation. Patients with no response to neoadjuvant chemotherapy were treated with surgery and/or radiotherapy. After completion of local therapy, chemotherapy was continued for four to 15 cycles, followed by radiotherapy. Patients older than 50 years who had estrogen receptor-positive tumors received tamoxifen for 5 years. RESULTS Median follow-up was 11.6 years (range, 4.8 to 22.6 years). Disease-free survival rates at 5 and 10 years were 34% and 32%, respectively. The median disease-free survival was 1.9 years. Overall survival rates at 5 and 10 years were 41% and 31%, respectively. The median overall survival was 3.5 years. The overall response rate (partial and complete responses) to induction chemotherapy was 89%. No treatment-related deaths occurred. CONCLUSION Patients with ipsilateral supraclavicular metastases but no other evidence of distant metastases warrant therapy administered with curative intent, ie, combined-modality therapy consisting of chemotherapy, surgery, and radiotherapy. Patients with ipsilateral supraclavicular metastases should be included in the stage IIIB category of the tumor-node-metastasis classification because their clinical course and prognosis are similar to those of patients with stage IIIB LABC.
Collapse
Affiliation(s)
- R A Brito
- Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Ibrahim NK, Valero V, Theriault RL, Willey J, Walters RS, Buzdar AU, Booser DJ, Hortobagyi GN. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol 2000; 23:117-21. [PMID: 10776969 DOI: 10.1097/00000421-200004000-00003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The purpose of this study was to evaluate the maximum tolerated dose and the toxicity profile of vinorelbine administered by continuous infusion for 96 hours to patients who had received prior chemotherapy for metastatic breast cancer. Forty-three patients with metastatic breast cancer were treated with vinorelbine 8 mg intravenously for 10 minutes (day 1) followed by continuous infusion of vinorelbine for 96 hours. Treatments were repeated every 3 weeks. Eighty-eight percent of the patients had had two or more prior chemotherapeutic regimens: 91% had prior doxorubicin therapy and 77% had prior paclitaxel therapy. All 43 patients were evaluable for toxicity. The median age was 49 years. All patients had a performance status less than or equal to 2 and a life expectancy more than 12 weeks. Eight dose levels were evaluated, and a total of 182 cycles were given. National Cancer Institute grade III or IV granulocytopenia was observed in 64 (35%) cycles, neutropenic fever in 27 (15%) cycles, fatigue (National Cancer Institute grade III or IV) in 18 (10%) cycles, and hand-foot syndrome in 8 (4%) cycles. In 17 (9%) cycles, patients were hospitalized. The maximum tolerated dose of this regimen was determined to be vinorelbine 8 mg intravenously for 10 minutes (day 1) followed by continuous vinorelbine infusion 11 mg/m2 for 96 hours. The dose-limiting toxicity was neutropenic fever and stomatitis.
Collapse
Affiliation(s)
- N K Ibrahim
- Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030-4009, USA
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 2000; 92:225-33. [PMID: 10655439 DOI: 10.1093/jnci/92.3.225] [Citation(s) in RCA: 132] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Uncontrolled studies have reported encouraging outcomes for patients with high-risk primary breast cancer treated with high-dose chemotherapy and autologous hematopoietic stem cell support. We conducted a prospective randomized trial to compare standard-dose chemotherapy with the same therapy followed by high-dose chemotherapy. PATIENTS AND METHODS Patients with 10 or more positive axillary lymph nodes after primary breast surgery or patients with four or more positive lymph nodes after four cycles of primary (neoadjuvant) chemotherapy were eligible. All patients were to receive eight cycles of 5-fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide (FAC). Patients were stratified by stage and randomly assigned to receive two cycles of high-dose cyclophosphamide, etoposide, and cisplatin with autologous hematopoietic stem cell support or no additional chemotherapy. Tamoxifen was planned for postmenopausal patients with estrogen receptor-positive tumors and chest wall radiotherapy was planned for all. All P values are from two-sided tests. RESULTS Seventy-eight patients (48 after primary surgery and 30 after primary chemotherapy) were registered. Thirty-nine patients were randomly assigned to FAC and 39 to FAC followed by high-dose chemotherapy. After a median follow-up of 6.5 years, there have been 41 relapses. In intention-to-treat analyses, estimated 3-year relapse-free survival rates were 62% and 48% for FAC and FAC/high-dose chemotherapy, respectively (P =.35), and 3-year survival rates were 77% and 58%, respectively (P =.23). Overall, there was greater and more frequent morbidity associated with high-dose chemotherapy than with FAC; there was one septic death associated with high-dose chemotherapy. CONCLUSIONS No relapse-free or overall survival advantage was associated with the use of high-dose chemotherapy, and morbidity was increased with its use. Thus, high-dose chemotherapy is not indicated outside a clinical trial.
Collapse
Affiliation(s)
- G N Hortobagyi
- Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Booser DJ, Walters RS, Holmes FA, Hortobagyi GN. Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: a phase II study. Am J Clin Oncol 2000; 23:40-1. [PMID: 10683074 DOI: 10.1097/00000421-200002000-00011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Twelve women with metastatic breast cancer were treated with continuous infusion high dose leucovorin, 5-fluorouracil and cisplatin. Toxicity was severe although the dose was lower than previously described for the treatment of other cancers, and there was little anti-tumor activity. Many other regimens are more effective and less toxic.
Collapse
Affiliation(s)
- D J Booser
- Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | |
Collapse
|
25
|
Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau SW, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999; 17:3412-7. [PMID: 10550135 DOI: 10.1200/jco.1999.17.11.3412] [Citation(s) in RCA: 173] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
PURPOSE To compare prospectively the antitumor activity of single-agent paclitaxel to the three-drug combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC) as neoadjuvant therapy in patients with operable breast cancer. PATIENTS AND METHODS Patients with T1-3N0-1M0 disease were randomized to receive either paclitaxel (250 mg/m(2)) as 24-hour infusion or FAC in standard doses at every-3-week intervals. Each patient was treated with four cycles of preoperative chemotherapy. Clinical response and extent of residual disease in the breast and lymph nodes was assessed after four cycles of induction chemotherapy. RESULTS A total of 174 patients were registered, and 87 were randomized to each arm of the study. Clinical response, ie, complete and partial responses, was similar in both arms of the study. Three patients in the FAC arm and one patient in the paclitaxel subgroup had progressive disease. The extent of residual disease by intent-to-treat analysis at the time of surgery was similar between the two arms of the study. CONCLUSION The results of this prospective study demonstrated that single-agent paclitaxel as neoadjuvant therapy has significant antitumor activity, and this was clinically comparable to FAC. Similar fractions of patients had clinical complete and partial responses, and very few patients had no response to either therapy. The value of alternate non-cross-resistant therapies as used in this protocol on the clinical course of this disease would require longer follow-up.
Collapse
Affiliation(s)
- A U Buzdar
- University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, Fraschini G, Buzdar AU, Willey J, Frye D, Asmar L, Hortobagyi GN. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol 1999; 10:403-11. [PMID: 10370782 DOI: 10.1023/a:1008360406322] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
PURPOSE We and others have demonstrated the antineoplastic efficacy of paclitaxel as a single agent in metastatic breast cancer. We performed this phase I trial to evaluate the combination of paclitaxel with doxorubicin. PATIENTS AND METHODS Eligible patients had measurable or evaluable metastatic breast cancer for which this was the initial cytotoxic treatment. They may have received adjuvant chemotherapy with other drugs. The study had four parts. In part 1, the patients received paclitaxel by 24-hour infusion followed by doxorubicin by 48-hour infusion. The paclitaxel dose was to be escalated from a starting dose of 125 mg/m2, and the doxorubicin dose was to remain constant at 60 mg/m2 with treatment repeated every three weeks. The results of part 1 prompted part 2 which was a study of the reverse sequence. Part 3 was a formal study of pharmacology and has been reported (J Clin Oncol 14: 2713-21, 1996). In part 4, patients received doxorubicin 50 mg/m2 by bolus followed by paclitaxel 150 mg/m2 by 24-hour infusion for courses 1 and 2. In all subsequent courses doxorubicin was administered by 48-hour infusion. All patients in all four parts of the study had baseline cardiac scans. All patients received standard premedication for paclitaxel. RESULTS Forty-eight patients were treated in all four parts of the study. In part 1 (10 patients), the maximum tolerated dose (MTD) was paclitaxel 125 mg/m2/24 hours followed by doxorubicin 48 mg/m2/48 hours as defined by dose-limiting mucositis and neutropenic fever which occurred at the starting dose. For part 2 (21 patients), the MTD was doxorubicin 60 mg/m2/48 hours followed by paclitaxel 160 mg/m2/24 hours. In part 4 (seven patients), the MTD was doxorubicin 50 mg/m2/bolus followed by paclitaxel 135 mg/m2/24 hours. In parts 2 and 4, the dose-limiting toxic effect was neutropenia. Of the entire cohort of 48 patients, seven (15%) had a complete response (one persists at five years without intervening therapy), 26 (54%) had a partial response for an objective response rate of 69% (95% confidence interval (95% CI): 54%-81%). The median follow-up of all living patients is 38+ months (range 20+ to 62+); the median response duration is seven months (range 2-33.7+); the median overall survival is 20.5 months (range 5-54+). The median time to progression is 9.6 months (range 1-33.7+ months). Two patients developed congestive heart failure, one at 24 months after her final dose of doxorubicin which amounted to a cumulative lifetime total doxorubicin dose of 870 mg/m2, one after a total of 660 mg/m2. In both, cardiac symptoms were controlled with medications. CONCLUSIONS The combination of paclitaxel/24 hours with doxorubicin/48 hours is an effective antineoplastic treatment for metastatic breast cancer. However, the incidence of complete response, the median overall survival, and time to progression were not greater than for standard doxorubicin-based combinations. Additionally, a sequence-dependent interaction between paclitaxel and doxorubicin, given in the schedule described here, was defined. Other strategies and schedules should be evaluated to maximize the antineoplastic efficacy of these two potent agents.
Collapse
Affiliation(s)
- F A Holmes
- Department of Breast Medical Oncology, University of Texas, M.D. Anderson Cancer Centre, Houston, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Berry DL, Theriault RL, Holmes FA, Parisi VM, Booser DJ, Singletary SE, Buzdar AU, Hortobagyi GN. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999; 17:855-61. [PMID: 10071276 DOI: 10.1200/jco.1999.17.3.855] [Citation(s) in RCA: 334] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE No standardized therapeutic interventions have been reported for patients diagnosed with breast cancer during pregnancy. Of the potential interventions, none have been prospectively evaluated for treatment efficacy in the mother or safety for the fetus. We present our experience with the use of combination chemotherapy for breast cancer during pregnancy. PATIENTS AND METHODS During the past 8 years, 24 pregnant patients with primary or recurrent cancer of the breast were managed by outpatient chemotherapy, surgery, or surgery plus radiation therapy, as clinically indicated. The chemotherapy included fluorouracil (1,000 mg/m2), doxorubicin (50 mg/m2), and cyclophosphamide (500 mg/m2), administered every 3 to 4 weeks after the first trimester of pregnancy. Care was provided by medical oncologists, breast surgeons, and perinatal obstetricians. RESULTS Modified radical mastectomy was performed in 18 of the 22 patients, and two patients were treated with segmental mastectomy with postpartum radiation therapy. This group included patients in all trimesters of pregnancy. The patients received a median of four cycles of combination chemotherapy during pregnancy. No antepartum complications temporally attributable to systemic therapy were noted. The mean gestational age at delivery was 38 weeks. Apgar scores, birthweights, and immediate postpartum health were reported to be normal for all of the children. CONCLUSION Breast cancer can be treated with chemotherapy during the second and third trimesters of pregnancy with minimal complications of labor and delivery.
Collapse
Affiliation(s)
- D L Berry
- Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN, Burris HA. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998; 16:3362-8. [PMID: 9779713 DOI: 10.1200/jco.1998.16.10.3362] [Citation(s) in RCA: 168] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To evaluate the efficacy and safety of docetaxel in patients with paclitaxel-resistant metastatic breast cancer (MBC). PATIENTS AND METHODS Docetaxel (100 mg/m2) was administered every 3 weeks to 46 patients registered at four centers. Patients had previously received < or = two chemotherapy regimens for MBC. All patients had progressive disease while receiving paclitaxel therapy. Treatment was repeated until there was evidence of disease progression or for a maximum of three cycles after best response. RESULTS Objective responses were seen in eight of 44 assessable patients (18.1%; 95% confidence interval [CI], 6.7% to 29.5%). Seven patients had partial responses and one patient responded completely. Response rates were not significantly different by previously received paclitaxel dose or resistance. No responses were seen in 12 patients who had previously received paclitaxel by 24-hour infusion, but the response rate in 32 patients who had received paclitaxel by 1- to 3-hour infusion was 25%. The median response duration was 29 weeks and the median time to disease progression was 10 weeks. Median survival was 10.5 months. Clinically significant (severe) adverse events included neutropenic fever (24% of patients), asthenia (22%), infection (13%), stomatitis (9%), neurosensory changes (7%), myalgia (7%), and diarrhea (7%). CONCLUSION Docetaxel is active in patients with paclitaxel-resistant breast cancer, particularly in those who failed to respond to brief infusions of paclitaxel. Response rates were comparable to or better than those seen with other therapies for patients with paclitaxel-resistant MBC. This confirms preclinical studies, which indicated only partial cross-resistance between paclitaxel and docetaxel.
Collapse
Affiliation(s)
- V Valero
- The University of Texas M.D. Anderson Cancer Center, Houston 77030-4095, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1996; 14:2713-21. [PMID: 8874332 DOI: 10.1200/jco.1996.14.10.2713] [Citation(s) in RCA: 122] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
PURPOSE To determine whether a schedule-dependent interaction occurs when paclitaxel and doxorubicin are administered sequentially. PATIENTS AND METHODS Ten patients with metastatic breast cancer received paclitaxel 125 mg/m2 over 24 hours either immediately before or after doxorubicin 48 mg/m2 over 48 hours as the initial chemotherapy treatment. Two such courses were given, and the sequence of administration was reversed after course 1. In cohort 1, paclitaxel preceded doxorubicin for course 1. In cohort 2, doxorubicin preceded paclitaxel for course 1. Doxorubicin levels were measured serially during the infusion and for 24 hours following it. Patients were assessed clinically for the occurrence of stomatitis and infection and granulocyte counts were measured twice weekly. RESULTS Eight patients had complete pharmacokinetic sampling for both courses. The mean end-of-infusion plasma doxorubicin concentrations (Cmax) were 70% higher in the paclitaxel-doxorubicin sequence compared with the reverse sequence (45 +/- 8 ng/mL v 26 +/- 5 ng/ mL). The mean doxorubicin clearance was 32% lower in the paclitaxel-doxorubicin sequence (34.3 +/- 10.3 L/h v 51.6 +/- 16.1 L/h, P < .01). Clinically, hematologic and mucosal toxic effects were worse in the paclitaxel-doxorubicin sequence. The median absolute granulocyte count was 0.2/microL in the paclitaxel-doxorubicin sequence and 1.3/microL in the doxorubicin-paclitaxel sequence. Seven of 10 patients who received the paclitaxel-doxorubicin sequence had grade 2 (n = 4) or 3 (n = 3) stomatitis, while only one of 10 patients who received the doxorubicin-paclitaxel sequence had grade 2 stomatitis and none had grade 3. CONCLUSION When paclitaxel by 24-hour infusion precedes doxorubicin by 48-hour infusion, doxorubicin clearance is reduced by nearly one third, which results in grade 2 and 3 stomatitis. To prevent this effect when paclitaxel (by 24-hour infusion) and doxorubicin are administered sequentially, doxorubicin should be given first. The mechanisms for this effect are under investigation.
Collapse
Affiliation(s)
- F A Holmes
- Department of Breast Medical Oncology, University of Texas, M.D. Anderson Cancer Center, Houston
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Walters RS, Theriault RL, Booser DJ, Esparza L, Hortobagyi GN. Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer. J Immunother Emphasis Tumor Immunol 1995; 18:185-7. [PMID: 8770774 DOI: 10.1097/00002371-199510000-00006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Twenty-six patients with metastatic breast cancer were offered a phase II combination of recombinant alpha-interferon and continuous-infusion 5-fluorouracil (5-FU). 5-FU was administered at 750 mg/m2 daily for 5 days as a continuous infusion and recombinant interferon at 5 million U/m2 subcutaneously days 1,3, and 5 of each course. The courses were repeated every 14 days. Despite moderate nonmyelosuppressive toxicity, only two (8%) partial remissions were observed. In this schedule, the addition of recombinant alpha-interferon to conventional continuous-infusion 5-FU resulted in a response rate of 8%.
Collapse
Affiliation(s)
- R S Walters
- Department of Breast and Gynecologic Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030-4009, USA
| | | | | | | | | |
Collapse
|
31
|
Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am 1995; 4:715-34. [PMID: 8535907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Seven hundred fifty-two patients with stage III disease (of those, 178 patients with inflammatory carcinoma) were treated with a combined modality approach at our institute in seven prospective studies. After three to four cycles of chemotherapy, each patient was treated with local therapy. An estimated 54% of patients with stage IIIA disease and 24% of patients with stage IIIB disease were free of disease. An estimated 30% of patients with inflammatory carcinoma of breast were free of disease beyond 10 years with this approach.
Collapse
Affiliation(s)
- A U Buzdar
- University of Texas M.D. Anderson Cancer Center, Houston, USA
| | | | | | | | | | | |
Collapse
|
32
|
Abstract
30 years ago an anthracycline antibiotic was shown to have antineoplastic activity. This led to the development of well over 1000 analogues with a vast spectrum of biochemical characteristics. Many biological actions have been described. The original anthracyclines are active against many types of cancer and are an integral part of several curative combinations. They are ineffective against other tumours. Although some analogues show an altered spectrum of activity or an improved therapeutic index relative to the older agents, it is not clear that cardiotoxicity can be totally avoided with these agents. Primary and secondary resistance to anthracyclines remain major clinical problems. Pharmacokinetic studies have been of limited help in explaining this. Overexpression of a surface-membrane permeability glycoprotein (Pgp) was identified in ovarian cancer of patients who had clinical multidrug resistance in 1985. This led the way for the discovery of a number of resistance mechanisms in vitro. Some of these have been found in more than 1 type of cell line, and more than 1 mechanism may exist in a single cell. Additional resistance proteins have been identified, qualitative and quantitative alterations of topoisomerase II have been described, and some mechanisms in other systems have not yet been identified. Some of these may prove to be important in clinical drug resistance. Drugs such as calcium antagonists and cyclosporin, studied initially for their ability to block the Pgp pump, appear to be heterogeneous in this capacity and may have additional sites of action. It will be critical for clinical studies to define the precise resistance mechanism(s) that must be reversed. To date this has been difficult, even in trials ostensibly dealing with the original Pgp. Liposomes can potentially alter toxicity and target drug delivery to specific sites. In addition, they may permit the use of lipophilic drugs that would otherwise be difficult to administer systemically. Resistant tumours may be sensitive to anthracyclines delivered by liposomes. To reduce cardiac toxicity, administering doxorubicin (adriamycin) by slow infusion through a central-venous line should be considered whenever feasible. Monitoring of cardiac ejection fraction and the use of endomyocardial biopsy will permit patients to be treated safely after they reach the dose threshold at which heart failure begins to be a potential risk. A number of structurally modified anthracyclines with the potential advantages of decreased cardiotoxicity and avoidance of multidrug resistance mechanisms are entering clinical trials. Meanwhile, the vast weight of clinical experience leaves doxorubicin as a well tolerated and effective choice for most potentially anthracycline-sensitive tumours.
Collapse
Affiliation(s)
- D J Booser
- University of Texas, M.D. Anderson Cancer Center, Houston
| | | |
Collapse
|
33
|
Buzdar AU, Hortobagyi GN, Frye D, Ho D, Booser DJ, Valero V, Holmes FA, Birmingham BK, Bui K, Yeh C. Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J Clin Oncol 1994; 12:50-4. [PMID: 8270984 DOI: 10.1200/jco.1994.12.1.50] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
PURPOSE We studied the bioequivalence of a new once-daily regimen of tamoxifen citrate relative to the standard twice-daily regimen of tamoxifen citrate, an established antiestrogenic treatment for breast cancer. PATIENTS AND METHODS Of 30 women with breast cancer, 27 completed this open, two-period, crossover randomized trial. During one 3-month period, patients took one standard 10-mg tamoxifen tablet twice daily; during the preceding or following 3-month period, patients took one of the new 20-mg tablets once daily. Pharmacokinetic profiles and safety parameters were assessed at the end of each 3-month treatment period. RESULTS Overall, measured concentrations of tamoxifen and its principal active metabolite, N-desmethyltamoxifen, remained relatively constant over the 24-hour sampling periods at the end of each treatment sequence. For both compounds, the percentage differences of the geometric means for all pharmacokinetic parameters indicated bioequivalence of the once-daily regimen of tamoxifen relative to the standard twice-daily regimen. Both treatment sequences were well tolerated; reported adverse events occurred at similar frequencies with the two treatment regimens. CONCLUSION The 20-mg tamoxifen tablet taken once daily was bioequivalent to the 10-mg tamoxifen tablet taken twice daily, with no difference in relative risk. The once-daily treatment is a simpler regimen and may facilitate compliance, which may enhance therapeutic outcomes during long-term treatment of breast cancer.
Collapse
Affiliation(s)
- A U Buzdar
- Division of Medicine, University of Texas M.D. Anderson Cancer Center, Houston 77030
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Booser DJ, Hortobagyi GN. Treatment of locally advanced breast cancer. Semin Oncol 1992; 19:278-85. [PMID: 1609294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
It is possible to convert most patients with stage III breast cancer to the state of "no evidence of disease." The challenges now are to increase the cure rate by eradicating local and distant micrometastatic disease, and to minimize the mutilation of locoregional treatment.
Collapse
Affiliation(s)
- D J Booser
- Department of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030
| | | |
Collapse
|
35
|
Umsawasdi T, Valdivieso M, Booser DJ, Barkley HT, Ewer M, MacKay B, Dhingra HM, Murphy WK, Spitzer G, Chiuten DF. Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer. Cancer 1989; 64:1995-2000. [PMID: 2553235 DOI: 10.1002/1097-0142(19891115)64:10<1995::aid-cncr2820641004>3.0.co;2-l] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
A prospective randomized study was done to determine the effect of different doxorubicin (Adriamycin [ADR], Adria Laboratories, Columbus, OH) administration (schedules every week versus every 3 weeks) on the productivity of a cyclophosphamide, ADR, cisplatin (CAP) chemotherapy regimen for patients with non-small cell lung cancer (NSCLC). Electrocardiograms, multigated cardiac scans, echocardiograms, and endomyocardial biopsies were done serially for cardiac monitoring. Of 102 patients, 47 ahd inoperable limited disease (LD), 47 had extensive disease (ED), and eight had no evidence of disease. In the last group chemotherapy was given adjuvantly. Fifty-one patients were entered into each treatment arm. The groups were formed according to extent of disease and were comparable in terms of patient characteristics. In these groups, the overall response rates using both schedules in LD patients were similar: in patients without chest irradiation previously, there was a response of 35% with ADR weekly, and 31% with ADR triweekly; in LD patients with chest irradiation previously, the response was 20% with ADR weekly, and 25% with ADR triweekly; and in ED patients, 16% with ADR weekly, and 11% with ADR triweekly. There was no significant difference in survival between the two treatment groups. However, results for all responders suggested a longer duration of response with weekly than with triweekly ADR (complete plus partial response: 35.8 versus 11.4 weeks, P = 0.06; minor response: 34 versus 11.5 weeks, P = 0.003, respectively). Results also suggested that weekly ADR was less cardiotoxic than triweekly ADR: 29% of patients in the former group had no changes or only minor changes in endomyocardial biopsy results, whereas all patients in the latter group had at least grade 0.5 changes at a similar dosage. The median doses of weekly ADR were higher at the same endomyocardial biopsy-defined toxicity levels. No correlation was found between toxic effects defined by endomyocardial biopsy results and those defined by noninvasive monitoring techniques, although the number of patients assessed was small. Weekly ADR produced less granulocytopenia and a lower incidence of fever (6% versus 16%, P less than 0.001) than did triweekly ADR. Alopecia, nausea, vomiting, and diarrhea were significantly less for weekly ADR than triweekly Adr (P less than 0.0005, less than 0.0005, and less than 0.005, respectively). These data suggest that weekly ADR can achieve the same therapeutic results as the standard triweekly regimen with less cardiotoxicity, myelotoxicity, alopecia, diarrhea, nausea, and vomiting in patients with NSCLC.
Collapse
Affiliation(s)
- T Umsawasdi
- Department of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Umsawasdi T, Valdivieso M, Barkley HT, Chen T, Booser DJ, Chiuten DF, Dhingra HM, Murphy WK, Carr DT. Combined chemoradiotherapy in limited-disease, inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1988; 14:43-8. [PMID: 3335461 DOI: 10.1016/0360-3016(88)90049-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Forty-three patients with limited-disease, inoperable non-small cell lung cancer received two intravenous courses of cyclophosphamide, Adriamycin, and cisplatin (CAP) chemotherapy over a 6-week period. This was followed by 5 weeks of combined chemoradiotherapy (CCRT) consisting of low weekly doses of CAP for 5 weeks plus 50 Gy continuous X ray therapy (XRT) to the primary tumor site. Chemotherapy was continued until disease progression occurred or until the total dose of Adriamycin reached 450 mg/m2, whichever came first. CCRT improved the response rate [complete response (CR) plus partial responses (PR)] from 25% after two courses of CAP alone to 65% after CCRT. Previous response to two courses of CAP influences response subsequent to CAP plus XRT. A pretherapy weight loss of 6% or greater had a significant adverse effect on both response and survival time. The median survival time for all patients was 50 weeks; patients whose disease responded to treatment survived significantly longer than patients with nonresponding disease. The median time until disease progression was 37 weeks. Twenty-seven patients relapsed. The first sites of relapse were local in 30% of the patients, distant in 56% of them, and both local and distant in 15%. Severe esophagitis occurred in 30% of the patients and was dose-limiting. The administration of CCRT resulted in an improved response rate compared with the rates reported in previous studies of chemotherapy or radiotherapy alone. Further improvement of the CCRT program is needed to increase long-term survival time and to decrease esophageal toxicity.
Collapse
Affiliation(s)
- T Umsawasdi
- Department of Medical Oncology, UT M.D. Anderson Hospital, Houston 77030
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Umsawasdi T, Valdivieso M, Barkley HT, Booser DJ, Chiuten DF, Murphy WK, Dhingra HM, Dixon CL, Farha P, Spitzer G. Esophageal complications from combined chemoradiotherapy (cyclophosphamide + Adriamycin + cisplatin + XRT) in the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1985; 11:511-9. [PMID: 3838297 DOI: 10.1016/0360-3016(85)90182-8] [Citation(s) in RCA: 36] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Esophageal complications from combined chemoradiotherapy (CCRT) were analyzed in 55 patients with limited non-small cell lung cancer. CCRT consisted of chemotherapy (cyclophosphamide, doxorubicin (Adriamycin), and cisplatin: CAP) and chest irradiation (5000 rad in 25 fractions/5 weeks). Forty-five patients received two courses of CAP, followed by five weekly courses of low dose CAP and irradiation followed by maintenance courses of CAP (Group 1). Ten patients received concomitant CCRT from the onset of treatment (Group 2). Esophagitis occurred in 80% of all patients. Severe esophagitis occurred in 27% of patients of Group 1 and 40% of patients of Group 2. Esophageal stricture or fistula developed in 1 of 45 (2%) patients in Group 1, and 3 of 10 (30%) patients in Group 2 (p less than 0.025). Weekly low-dose chemotherapy administered concomitantly with chest irradiation (R) at the onset of treatment significantly increases esophageal complications. A review of the literature suggests that CCRT may be used safely with split courses of R. The duration between onset of chemotherapy either before or after R should be greater than one week.
Collapse
|
38
|
Umsawasdi T, Valdivieso M, Chen TT, Barkley HT, Booser DJ, Chiuten DF, Dhingra HM, Murphy WK, Dixon CL, Farha P. Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer. J Neurooncol 1984; 2:253-9. [PMID: 6389779 DOI: 10.1007/bf00253278] [Citation(s) in RCA: 115] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
We have studied the clinical impact of elective brain irradiation (EBI) in patients with locally advanced, non-small cell lung cancer (LA-NSC). All patients received combination chemotherapy (cyclophosphamide + doxorubicin (Adriamycin) + cisplatin = CAP) or CAP plus radiotherapy as the initial treatment for their active tumor or as an adjuvant therapy. Of 97 evaluable patients, 46 were randomized to receive EBI (3 000 rad in 10 fractions given over two weeks). The characteristics of both groups were comparable by sex, age, performance status, pretherapy weight loss, histologic cell type, clinical staging, and type of prior therapy. EBI significantly decreased the incidence of central nervous system (CNS) metastasis in the treated group compared to the control group (4% vs 27%, p = .002). CNS involvement occurred in the treated group after failure at other sites whereas 12 of 14 control patients had CNS metastases as the first site of relapse. EBI decreased the incidence of CNS metastasis in all prognostic categories. Using multivariate analysis, the beneficial effect was shown to be significant in females, patients with good performance status, weight loss less than 6%, squamous cell histology, state III disease or no prior therapy. EBI significantly increased CNS metastasis-free interval with a beneficial effect that was significant in males, patients with weight loss less than 6%, squamous cell histology or responders. Although no survival benefit was observed for the treated group because of the adverse effect from other relapses, EBI will become more important as better treatment programs are developed.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
39
|
Valdivieso M, Umsawasdi T, Spitzer G, Chiuten DF, Booser DJ, Dhingra HM, Bodey GP. Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung cancer. Am J Clin Oncol 1984; 7:241-4. [PMID: 6328968 DOI: 10.1097/00000421-198406000-00008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
A phase II clinical study of dihydroxyanthracenedione ( DHAD ) was conducted in 50 patients with advanced lung cancers. DHAD was administered intravenously on a 5-day schedule repeated every 4 weeks. Most patients had adenocarcinoma (46%), and had received previous chemotherapy (66%) and radiation therapy (50%). Among 41 evaluable patients, there were four partial remissions, eight disease stabilizations and 29 disease progressions. Remissions were more common among previously untreated patients (20% vs. 4%), particularly in patients with adenocarcinoma and large cell carcinomas of whom 3/10 (30%) responded. Responses lasted 9+, 9, 7, and 3 months, respectively. Cardiac toxicity was not observed. Other toxicities were tolerable. DHAD is a potentially useful agent for the therapy of adenocarcinoma and large cell lung cancers.
Collapse
|
40
|
Dhingra HM, Valdivieso M, Booser DJ, Umsawasdi T, Carr DT, Chiuten DF, Murphy WK, Issell BF, Spitzer G, Farha P. Chemotherapy for advanced adenocarcinoma and squamous cell carcinoma of the lung with etoposide and cisplatin. Cancer Treat Rep 1984; 68:671-3. [PMID: 6538811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Forty-one patients with unselected advanced non-small cell lung cancer were treated with a combination of etoposide and cisplatin. A response rate of 19%, a 78-week median survival of responders, and a 36-week overall median survival were observed.
Collapse
|
41
|
|